All In Biotech

BLA 761344 · Amgen INC

Imdelltra

Tarlatamab-Dlle · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, May 16, 2024: To treat extensive stage small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

May 16, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

40

8 Phase 3, 20 recruiting

FAERS reports

10

10 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA. Initiate IMDELLTRA using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.5) and Warnings and Precautions (5.1) ] . Neurologic toxicity and immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment and treat promptly. Withhold IMDELLTRA until ICANS resolves or permanently discontinue based on severity [see Dosage...

What it is approved for

From the label in effect Sep 11, 2026.

IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum - based chemotherapy. ( 1 )

Mechanism: Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 2025 Supplement 1 · Efficacy · priority review OrphanLabelLetter
  • May 16, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • IMDELLTRA · TARLATAMAB-DLLE 1MG · INJECTABLE, INJECTION · Prescription
  • IMDELLTRA · TARLATAMAB-DLLE 10MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tarlatamab" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome4
  • immune effector cell-associated neurotoxicity syndrome4
  • acute respiratory failure2
  • dyspnoea2
  • fatigue2
  • pain2
  • adverse event1
  • asthenia1
  • atrial fibrillation1
  • cardio-respiratory arrest1
  • cardiomyopathy1
  • cardiovascular disorder1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20243
20253
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imdelltra (Tarlatamab-Dlle)

2024 spending

$483K

Beneficiaries

n/a

26 claims

Per beneficiary

n/a

$10,867.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$483,436

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.